Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 219,514,000	$ 117,483,000	$ 120,368,000
Operating expenses:
Research and development	29,843,000	17,204,000	14,851,000
Selling and marketing	79,840,000	52,389,000	53,691,000
General and administrative	101,353,000	36,729,000	29,029,000
Intangible asset amortization	15,981,000	5,095,000	1,401,000
Total operating expenses	301,417,000	152,872,000	135,495,000
Loss from operations	(81,903,000)	(35,389,000)	(15,127,000)
Other income, net	254,000	480,000	2,528,000
Loss before income tax benefit	(81,649,000)	(34,909,000)	(12,599,000)
Income tax benefit	(6,086,000)	0	0
Net loss	$ (75,563,000)	$ (34,909,000)	$ (12,599,000)
Net loss per common share, basic (in USD per share)	$ (1.11)	$ (0.66)	$ (0.27)
Net loss per common share, diluted (in USD per share)	$ (1.11)	$ (0.66)	$ (0.27)
Shares use to compute net loss per common share, basic (in shares)	67,890,328	53,239,231	46,138,177
Shares use to compute net loss per common share, diluted (in shares)	67,890,328	53,239,231	46,138,177
Testing revenue
Revenue:
Total revenue	$ 188,182,000	$ 101,970,000	$ 107,355,000
Operating expenses:
Cost of revenue	58,860,000	35,913,000	36,077,000
Product revenue
Revenue:
Total revenue	11,464,000	9,845,000	923,000
Operating expenses:
Cost of revenue	5,887,000	4,921,000	446,000
Biopharmaceutical and other revenue
Revenue:
Total revenue	19,868,000	5,668,000	12,090,000
Operating expenses:
Cost of revenue	$ 9,653,000	$ 621,000	$ 0